Clinical trials: Non-squamous NSCLC
Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors.
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
- Trial name
- NCT07227298
- Testing
- PF-08634404, Sigvotatug Vedotin, PF-08046054/SGN-PDL1V
- Where
- 104 sites in United States, China and 7 more
- Volunteers
- 162 people
- Sponsor
- Pfizer
Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
This is a single center, open-label phase I clinical trial designed to determine the safety of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab in subjects with…
- Conditions
- Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- PANDA-VAC (NCT04266730)
- Testing
- PANDA-VAC, Pembrolizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Locally Advanced or Metastatic Epithelial Tumor
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
In phase Ia study, the safety and tolerability of SI-B001 in patients with locally advanced or metastatic epithelial malignancies will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of…
- Trial name
- NCT04603287
- Testing
- SI-B001
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous…
- Trial name
- TRITON (NCT06008093)
- Testing
- Durvalumab, Tremelimumab, Pemetrexed
- Where
- 47 sites in United States
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
Lung Cancer
Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00438204
- Testing
- bevacizumab, gemcitabine hydrochloride, pemetrexed disodium
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies.
- Conditions
- Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Trial name
- NCT06974734
- Testing
- PF-08046037, sasanlimab
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 8 people
- Sponsor
- Pfizer
Lung Cancer Metastatic
Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC
This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase inhibitors of vascular endothelial growth factor receptor 2（VEGFR）、FGFR（fibroblast growth factor receptor）, platelet-derived growth factor…
- Trial name
- NCT03706287
- Testing
- anlotinib 8mg + AP/PC, anlotinib 10mg + AP/PC, anlotinib 12mg + AP/PC
- Where
- 6 sites in China
- Volunteers
- 62 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Non-small Cell Lung Cancer Stage IV
Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis
This is a multicenter, national, nonrandomized, phase II trial in subjects with nonsquamous NSCLC patients that have untreated asymptomatic BM.
- Trial name
- ATEZO-BRAIN (NCT03526900)
- Testing
- Atezolizumab
- Where
- 15 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Spanish Lung Cancer Group
Lung Squamous Cell Carcinoma
A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy
To compare the efficacy and safety of 7MW3711 versus docetaxel in patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) .
- Trial name
- NCT07831863
- Testing
- 7MW3711, Docetaxel
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Non Squamous Cell Lung Cancer, Non Small Cell Lung Cancer
Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC
The purpose of this study is to assess the 2-month progression-free survival in patients with advanced or metastatic, non-squamous cell lung cancer treated with weekly low dose docetaxel in combination with a biologic dose of…
- Trial name
- NCT00801801
- Testing
- Docetaxel + Sorafenib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Francisco Robert,MD
Lung Cancer
Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy
The goal of this clinical research study is to evaluate the outcome of a standard radiation treatment called stereotactic radiotherapy (SRT) for NSCLC.
- Trial name
- NCT02357992
- Testing
- Stereotactic Body Radiotherapy (SABR)
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- M.D. Anderson Cancer Center
Nonsquamous Nonsmall Cell Neoplasm of Lung
Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab
This is a pharmacogenomic study with carboplatin, paclitaxel and bevacizumab as first line therapy in patients with non-squamous advanced non-small cell lung cancer.
- Trial name
- ANGIOMET (NCT01814163)
- Testing
- paclitaxel, carboplatin and bevacizumab
- Where
- 20 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Spanish Lung Cancer Group
Non-Small-Cell Lung Cancer
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
The aim of this phase Ⅱ study is to evaluate the efficacy and safety of Furmonertinib combined with Anlotinib as the first-line treatment in locally advanced or metastatic non-small cell lung cancer with sensitive EGFR mutations.
- Trial name
- FOCUS-A (NCT04895930)
- Testing
- Furmonertinib, Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Chest Hospital
Urothelial Carcinoma, Triple Negative Breast Cancer
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, dose-escalation and expansion study designed to investigate SBT6290 administered alone and in combination with pembrolizumab in advanced solid tumors associated with Nectin-4…
- Conditions
- Urothelial Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05234606
- Testing
- SBT6290, pembrolizumab
- Sponsor
- Silverback Therapeutics
Lung Cancer
LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
ABRAXANE, based on results from prior studies, is a promising drug in squamous cell carcinoma of the lung. This study will help to explore the combination of ABRAXANE and carboplatin more thoroughly in the subgroup of patients…
- Trial name
- NCT02328105
- Testing
- Carboplatin, Abraxane
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Wake Forest University Health Sciences
Lung Cancer
Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have metastatic…
- Trial name
- NCT00006877
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Solid Tumor, Advanced Solid Tumor
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
- Trial name
- NCT05479812
- Testing
- WTX-124, pembrolizumab
- Where
- 14 sites in United States
- Volunteers
- 156 people
- Sponsor
- Werewolf Therapeutics, Inc.
Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
The purpose of this study is to assess the safety and efficacy of pemetrexed + carboplatin + pembrolizumab (MK-3475) with lenvatinib (MK-7902/E7080) in patients with advanced nonsquamous non-small cell lung cancer harboring EGFR…
- Trial name
- NCT05258279
- Testing
- Pembrolizumab, Lenvatinib, Carboplatin
- Where
- 10 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Juntendo University
Non-small-cell Lung Cancer
Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer
This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab in combined with chemoradiotherapy for unresectable,local advanced squamous cell lung cancer.
- Trial name
- NCT02577341
- Testing
- Nimotuzumab, docetaxel and cisplatin, daily RT to the chest
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Sun Yat-sen University
Lung Cancer
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01414595
- Testing
- DNA analysis, DNA methylation analysis, RNA analysis
- Where
- 11 sites in United States
- Volunteers
- 248 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.